Law360, New York (March 02, 2012, 6:58 PM ET) -- Mylan Inc. on Friday vowed to appeal after a New York federal judge ruled that five patents asserted against Sunovion Pharmaceuticals Inc. in a suit over the chronic pulmonary obstructive disease drug Brovana were invalid, and limited potential damages on the two other patents-in-suit.
U.S. District Judge John Koeltl signed off on a 43-page opinion and order granting a motion for partial summary judgment from Dainippon Sumitomo Pharma Co. Ltd. unit Sunovion, concluding that the second of two families of patents being asserted by Mylan and...
Sunovion Knocks Out 5 Patents In Mylan's Brovana Suit
To view the full article, take a free trial now.
